12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Company News  |  Deals

BioMS, Eli Lilly deal

Lilly returned to BioMS all rights to dirucotide (formerly MBP8298), terminating a 2007 deal for exclusive, worldwide rights to the synthetic myelin basic protein (MBP) peptide...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >